PAK6 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, PAK6 has been found to be associated with radiosensitivity and chemosensitivity in prostate cancer [13, 29], chronic myeloid leukemia [12], and colon cancer [26], indicating the important role of PAK6 in cancer treatment response.